ATR‑04: A Promising Topical Biotherapeutic for EGFR Inhibitor–Induced Skin Rashes in Cancer Patients
A new clinical trial (June 2025) investigates ATR‑04, a microbiome-based topical therapy using engineered Staphylococcus epidermidis to treat EGFR inhibitor–related rashes. A breakthrough for side effect management in oncology. ATR‑04: ...